Contact lens maker Bausch + Lomb rules out take-private deal
Bausch + Lomb will not be taken private at this time, the contact lens maker said on Thursday.
Wall Street Analysts See a 25.5% Upside in Bausch (BHC): Can the Stock Really Move This High?
The mean of analysts' price targets for Bausch (BHC) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Bausch + Lomb CEO on the negative impact of screen time on eye health
Brent Saunders, Bausch and Lomb CEO, discusses how too much screen time can have a negative impact on vision.
Here's Why Bausch Health (BHC) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Contact lens maker Bausch + Lomb says it is exploring sale
Bausch + Lomb is exploring a potential sale among other options, it said on Thursday, in a move that would help Canadian parent Bausch Health exit the eye-care company.
Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb
LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO): "As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is one of several options being considered to complete the separation.
Bausch + Lomb And Bausch Health: Some Incremental Progress As We Wait For Sale News
Bausch Health Companies Inc.'s debt burden remains a critical issue, with over $21 billion in long-term debt, making a sale of Bausch + Lomb Corporation a potential solution. Bausch + Lomb's Q3 performance showed revenue growth and a shift to net income, driven by new products like Xiidra and Miebo. Despite bankruptcy rumors, major institutional investors like Carl Icahn and Paulson & Co. suggest strategic moves could prevent such an outcome.
Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation (OIC) Awareness Day
LAVAL, QC / ACCESSWIRE / December 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. This important day is dedicated to bringing awareness to a commonly-overlooked side effect of opioids.
Bausch Health Companies: Improving Core Business Cures Its Bankruptcy Rumors
Bausch Health Companies is undervalued, with a positive outlook for 2024 and solvency reassurance for 2025. The complete spin-off of Bausch + Lomb (B+L) will benefit BHC and is expected to improve its future profitability and financial health. BHC's innovative pipeline and proven track record of innovation will offset revenue loss from the spin-off and support future growth.
Why Is Bausch (BHC) Down 11.7% Since Last Earnings Report?
Bausch (BHC) reported earnings 30 days ago. What's next for the stock?
Bausch (BHC) Upgraded to Buy: Here's What You Should Know
Bausch (BHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
US Supreme Court declines to hear patent dispute over Bausch blockbuster diarrhea drug
The U.S. Supreme Court turned away on Monday a bid by Alvogen's subsidiary Norwich Pharmaceuticals to sell a generic version of Canada-based Bausch Health's blockbuster diarrhea drug Xifaxan.
